DOJ Cannabis Rescheduling Push Accelerates Federal Policy Overhaul

The Department of Justice advances its formal proposal to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act, representing the most substantive federal cannabis policy shift in decades. This administrative action follows months of review by the Drug Enforcement Administration and marks a critical juncture for the $33 billion U.S. cannabis market, which has operated under a complex patchwork of state-legal but federally-prohibited frameworks.

Rescheduling to Schedule III would fundamentally alter the tax burden facing cannabis operators by eliminating Section 280E restrictions that currently prevent businesses from deducting standard operating expenses. Multi-state operators like Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis have collectively paid hundreds of millions in additional taxes due to these limitations, with effective tax rates often exceeding 70% despite operating legally under state programs.

The proposal triggers a formal rulemaking process that includes public comment periods and potential legal challenges, creating uncertainty around implementation timelines. However, the Justice Department's backing provides unprecedented momentum for rescheduling advocates who have pushed for reform across multiple administrations. Cannabis equity markets have already begun pricing in potential benefits, with the AdvisorShares Pure US Cannabis ETF gaining over 40% since rescheduling speculation intensified earlier this year.

Beyond tax implications, Schedule III classification would enable cannabis companies to access traditional banking services more readily and potentially list on major U.S. exchanges without current regulatory obstacles. This shift could unlock institutional investment that has largely remained sidelined due to federal prohibition concerns, particularly from pension funds and major asset managers operating under fiduciary constraints.

The rescheduling momentum coincides with expanding state-level legalization, as 38 states now permit medical cannabis and 23 allow adult-use programs. Federal alignment with state policies would eliminate the regulatory arbitrage that has defined cannabis investing, potentially consolidating market leadership among operators with strong balance sheets and established distribution networks. The proposal represents a inflection point that could reshape cannabis from a niche alternative investment into a mainstream consumer goods sector.